newsfilter
← Latest News
Business Wire·

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Data presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today